Needham Buy initiation and $37 target ignite MPLT's 18% surge on positive pipeline outlook.
Multiple Wall Street firms recently initiated coverage with Buy ratings on the clinical-stage biopharmaceutical company, citing the differentiated potential of lead candidate ML-007C-MA (an M1/M4 muscarinic agonist) for schizophrenia and Alzheimer’s disease psychosis. Analysts highlighted billion-dollar commercial upside, favorable tolerability and dosing versus competitors like Cobenfy, robust Phase 2 enrollment (ZEPHYR trial targeting topline data in Q3 2026), completed enrollment in the IRIS trial for autism spectrum disorder (also Q3 readout), Fast Track designation, and a strong cash position of approximately $453 million providing runway into 2027. This coverage—Needham on or around April 8-9 with a $37 PT (significant upside from recent levels near $24), TD Cowen on April 7, plus earlier positive notes from Canaccord and Stifel—drove renewed buying interest. The stock broke to new 52-week highs above $25.79, with elevated volume and intraday gains reaching approximately 17-18% on April 9 as traders reacted to the implied valuation and near-term catalysts. No new company press release occurred on the 9th; the move reflects momentum from these verifiable analyst reports building on the March 2026 clinical and financial update.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.